Department of Interventional Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.
Department of Biomedical Engineering, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.
J Am Coll Cardiol. 2014 Dec 9;64(22):2343-56. doi: 10.1016/j.jacc.2014.09.029. Epub 2014 Dec 1.
Although recent observations suggest a favorable initial healing process of the everolimus-eluting bioresorbable vascular scaffold (BVS), little is known regarding long-term healing response.
This study assessed the in vivo vascular healing response using optical coherence tomography (OCT) 5 years after elective first-in-man BVS implantation.
Of the 14 living patients enrolled in the Thoraxcenter Rotterdam cohort of the ABSORB A study, 8 patients underwent invasive follow-up, including OCT, 5 years after implantation. Advanced OCT image analysis included luminal morphometry, assessment of the adluminal signal-rich layer separating the lumen from other plaque components, visual and quantitative tissue characterization, and assessment of side-branch ostia "jailed" at baseline.
In all patients, BVS struts were integrated in the vessel and were not discernible. Both minimum and mean luminal area increased from 2 to 5 years, whereas lumen eccentricity decreased over time. In most patients, plaques were covered by a signal-rich, low-attenuating layer. Minimum cap thickness over necrotic core was 155 ± 90 μm. One patient showed plaque progression and discontinuity of this layer. Side-branch ostia were preserved with tissue bridge thinning that had developed in the place of side-branch struts, creating a neo-carina.
At long-term BVS follow-up, we observed a favorable tissue response, with late luminal enlargement, side-branch patency, and development of a signal-rich, low-attenuating tissue layer that covered thrombogenic plaque components. The small size of the study and the observation of a different tissue response in 1 patient warrant judicious interpretation of our results and confirmation in larger studies.
尽管最近的观察结果表明依维莫司洗脱的生物可吸收血管支架(BVS)具有良好的初始愈合过程,但对于长期愈合反应知之甚少。
本研究通过光学相干断层扫描(OCT)评估选择性首例人类 BVS 植入后 5 年的体内血管愈合反应。
在鹿特丹胸科中心 ABSORB A 研究的 14 名存活患者中,有 8 名患者接受了侵入性随访,包括植入后 5 年的 OCT。先进的 OCT 图像分析包括管腔形态测量、评估将管腔与其他斑块成分分隔开的腔内膜信号丰富层、视觉和定量组织特征分析,以及评估在基线时“困住”的侧支开口。
在所有患者中,BVS 支架均整合在血管中且无法识别。最小和平均管腔面积从 2 年到 5 年增加,而管腔偏心度随时间减少。在大多数患者中,斑块被信号丰富、低衰减层覆盖。坏死核心上方的最小帽厚度为 155 ± 90 μm。1 名患者显示斑块进展且该层中断。侧支开口通过侧支支架处形成的组织桥变薄得以保留,从而形成新的嵴。
在 BVS 长期随访中,我们观察到有利的组织反应,表现为晚期管腔扩大、侧支通畅以及信号丰富、低衰减组织层的发展,该组织层覆盖了血栓形成的斑块成分。研究规模较小,且 1 名患者观察到不同的组织反应,因此需要对我们的结果进行谨慎解释,并在更大的研究中进行确认。